Remdesivir has 'little or no effect' on Covid-19 mortality: WHO study
Updated | By AFP
The antiviral drug remdesivir, considered one of the most promising Covid-19 treatments, turns out to do little to prevent deaths from the disease, according to a WHO-backed study.

Remdesivir, which was part of the experimental cocktail given to US President Donald Trump when he caught the new coronavirus last month, was one of several reviewed in a large study of more than 11,000 people across 30 countries.
The drug "appeared to have little or no effect on hospitalised COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay," said the study posted online late Thursday.
The data, which has yet to be peer-reviewed or published in a scientific journal, seems to contradict at least two major US studies that have shown that remdesivir can reduce the duration of hospital stays for COVID-19 patients.
Washington authorised the emergency use of the medicine, made by US pharmaceutical company Gilead Sciences and originally intended as a treatment for Ebola -- on May 1, followed by a range of other countries and the European Union.

Show's Stories
-
Shoppers pull epic prank on a PnP cashier
While this could've gone either way – how do you think the cashier took ...
Danny Guselli 10 minutes ago -
South African living in the US misses petrol attendants
It's the small things we take for granted in South Africa that make a bi...
Danny Guselli 11 minutes ago